Gabaculine

Mechanism of action

Gabaculine includes a comparable structure to GABA and a dihydrobenzene ring. This comparable GABA structure is used in order to be able to take the place of GABA during the first steps of transamination, including transaldimination and 1,3-prototrophic shift to the pyridoxamine imine. Following this, a proton from the dihydrobenzene ring is abstracted by an enzymatic base, thus causing the ring to become aromatic. The aromatic stabilization energy of the aromatic ring is what causes this reaction to be irreversible, thus causing the complex not to react further.

Preclinical studies

Animal studies to determine the effect of gabaculine on GABA levels in the brain were heavily conducted around the 1970s. These in vivo studies involved mostly the use of mice that underwent intravenous administration of this drug. Each of these studies concluded that gabaculine has a great potential to increase the GABA levels in the brain of these mice in a time dependent manner. Along with determining the effect of GABA levels, in vivo studies were conducted to investigate the ability of gabaculine to inhibit convulsions in mice. Results indicated that gabaculine provided a clear anticonvulsant effect against seizures induced by high doses of chemoconvulsants or electroshock. The toxicity of this compound was also investigated using animal mouse models. This study showed that at anticonvulsant doses, gabaculine is extremely potent and toxic when compared to other GABA transaminase inhibitors, with an ED50 of 35 mg/kg and of 86 mg/kg. Because of this potential lethal effect, gabaculine was proved to be too toxic for use as a drug however, it can still be used as a compound to alter GABA levels in studies of experimental epilepsy.

Regulation

Gabaculine has not been approved by the FDA as a pharmaceutical entity; however, it can be used as a chemical compound for research purposes only. This compound is not considered a hazardous substance according to OSHA 29 CFR 1910.1200.

References

References

1. (April 1977). "Isolation and inhibitory activity of gabaculine, a new potent inhibitor of gamma-aminobutyrate aminotransferase produced by a Streptomyces". FEBS Letters.
2. Rando RR. (October 1977). "Mechanism of the irreversible inhibition of gamma-aminobutyric acid-alpha-ketoglutaric acid transaminase by the neurotoxin gabaculine". Biochemistry.
3. (December 2007). "MK-801 enhances gabaculine-induced loss of the righting reflex in mice, but not immobility". Can J Anaesth.
4. Allan RD, Johnston GAR, Twitchin B. Effects of Gabaculine on uptake, binding and metabolism of GABA. ''Neuroscience Letters''. 1977;4:51-54.
5. (2006). "Structure-activity relationships of selective GABA uptake inhibitors". Current Topics in Medicinal Chemistry.
6. "Gabaculine Material Safety Data Sheet".
7. (1977). "Effects of gabaculine, a new potent inhibitor of gamma-aminobutyrate transaminase, on brain gamma-aminobutyrate content and convulsions in mice". Life Sciences.
8. (Dec 29, 2006). "Enzymatic Reaction Mechanism". Oxford University Press Inc..
9. (May 13, 1977). "The In Vivo Inhibition of GABA-transaminase by Gabaculine". Biochemical and Biophysical Research Communications.
10. (1980). "A Comparative Study of the Pharmacology of lnhibitors of GABA-Metabolism". Naunyn-Schmiedeberg's Arch. Pharmacol..
11. "Gabaculine". National Center for Biotechnology Information.